Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) EBT Margin (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of EBT Margin data on record, last reported at 101.68% in Q4 2025.

  • For Q4 2025, EBT Margin fell 8471.0% year-over-year to 101.68%; the TTM value through Dec 2025 reached 12.01%, up 1317.0%, while the annual FY2025 figure was 12.01%, 1317.0% up from the prior year.
  • EBT Margin reached 101.68% in Q4 2025 per APLS's latest filing, down from 47.17% in the prior quarter.
  • Across five years, EBT Margin topped out at 1770.4% in Q4 2022 and bottomed at 35183.15% in Q2 2021.
  • Average EBT Margin over 5 years is 2110.13%, with a median of 55.09% recorded in 2025.
  • Peak YoY movement for EBT Margin: skyrocketed 3423050bps in 2022, then tumbled -179681bps in 2023.
  • A 5-year view of EBT Margin shows it stood at 470.64% in 2021, then skyrocketed by 276bps to 1770.4% in 2022, then crashed by -101bps to 26.41% in 2023, then soared by 36bps to 16.97% in 2024, then crashed by -499bps to 101.68% in 2025.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 101.68% in Q4 2025, 47.17% in Q3 2025, and 23.35% in Q2 2025.